Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622282 | 0.89 | — | — | |
| SCHEMBL122934 | 0.89 | — | — | |
| Formaldehyde SCHEMBL28292213 | 0.87 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2EGFRTRIM24TRIM33 | |
| Formic Acid SCHEMBL27951317 | 0.82 | TRIM24 (0.47) | LMNASMN1; SMN2EGFRTRIM24TRIM33 | |
| SCHEMBL29132983 | 0.77 | TRIM24 (0.43) | LMNASMN1; SMN2EGFRTRIM24TRIM33 | |
| SCHEMBL937654 | 0.75 | TRPV4 (0.39) | TRIM24TRIM33MEN1KMT2ATDP1 | |
| SCHEMBL349118 | 0.72 | TRPV4 (0.51) | LMNASMN1; SMN2NFE2L2MEN1KMT2A | |
| SCHEMBL29435677 | 0.72 | TRPV4 (0.51) | LMNASMN1; SMN2NFE2L2MEN1KMT2A | |
| SCHEMBL11521127 | 0.71 | CA2 (0.52) | TDP1ALDH1A1 | |
| SCHEMBL1742387 | 0.71 | CA1 (0.56) | LMNASMN1; SMN2NFE2L2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| CN-103339111-B | Bicyclic acetyl-CoA carboxylase inhibitors | NOVARTIS AG (CH) | 2015-12-16 | — | — | CN | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| CN-103339111-A | Bicyclic acetyl-CoA carboxylase inhibitors | NOVARTIS AG | 2013-10-02 | — | — | CN | disclosed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | LMNA 2697/4885SMN1; SMN2 4695/4885EGFR 2169/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | LMNA 2697/4885SMN1; SMN2 4695/4885EGFR 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.